MedWatch

Award-winning researcher behind diabetes cell therapy: "I hope it can replace insulin"

Together with Eli Lilly, US-based Sigilon is developing a diabetes cell therapy that is to function as an insulin-producing artificial pancreas. Sigilon's co-founder, Robert Langer, hopes the therapy can replace insulin and even cure type 1 diabetes.

Robert Langer owns 1300 patents and has founded a wide range of companies. | Foto: Douglas A. Lockard/Science History Institute

Award-winning researcher and serial entrepreneur Robert Langer from Massachussets Institute of Technology (MIT) has high ambitions regarding his new inventions.

He is co-founder of the biopharmaceutical company Sigilon developing a cell therapy against diabetes to restore insulin production in the pancreas.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier